Dyax Corp.  

(Public, NASDAQ:DYAX)   Watch this stock  
Find more results for DYAX
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.21
Shares 147.18M
Beta     -
Inst. own 89%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -47.32% -14.53%
Operating margin -34.34% -1.51%
EBITD margin - -0.45%
Return on average assets -12.09% -6.76%
Return on average equity -14.86% -17.98%
Employees 124 -
CDP Score - -

Address

55 Network Dr
BURLINGTON, MA 01803-2756
United States - Map
+1-617-2505769 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.